Cargando…

Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study

AIM: To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Roehrborn, Claus G., Rosen, Raymond C., Manyak, Michael J., Palacios‐Moreno, Juan Manuel, Wilson, Timothy H., Lulic, Zrinka, Giuliano, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187250/
https://www.ncbi.nlm.nih.gov/pubmed/31927774
http://dx.doi.org/10.1111/ijcp.13480
_version_ 1783527135468584960
author Roehrborn, Claus G.
Rosen, Raymond C.
Manyak, Michael J.
Palacios‐Moreno, Juan Manuel
Wilson, Timothy H.
Lulic, Zrinka
Giuliano, François
author_facet Roehrborn, Claus G.
Rosen, Raymond C.
Manyak, Michael J.
Palacios‐Moreno, Juan Manuel
Wilson, Timothy H.
Lulic, Zrinka
Giuliano, François
author_sort Roehrborn, Claus G.
collection PubMed
description AIM: To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia. METHODS: This was a post hoc analysis of the Phase 4 FDC116115 study, in which patients aged ≥50 years were randomised 1:1 to receive a fixed‐dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (DUT‐TAM FDC), or placebo. End‐points included: change in MSHQ total scores by baseline characteristics and SexAEs; cumulative distribution function for change from baseline to month 12 in MSHQ total score and the ejaculation, erection, satisfaction and sexual desire (libido) domain scores; and relationship between changes in MSHQ scores and SexAEs. RESULTS: The intent‐to‐treat population comprised 489 patients (DUT‐TAM FDC, n = 243; placebo, n = 246). The mean reduction in total MSHQ score was greater in patients with SexAEs across both groups, compared with patients without SexAEs. Most patients reporting any SexAE (86% DUT‐TAM FDC, 67% placebo) had a worsening of the MSHQ total score at month 12 compared with baseline. Specifically, 90% (DUT‐TAM FDC) and 75% (placebo) of patients reporting an ejaculation SexAE and 73% (DUT‐TAM FDC) and 87% (placebo) of patients reporting an erection SexAE had a worsening of MSHQ ejaculation and erection domain scores, respectively, at month 12. A threshold effect for incident SexAE was observed; patients showing a decrease of approximately 6‐10 points in the total MSHQ score were more likely to report SexAEs. CONCLUSION: Findings support the clinical utility of the MSHQ tool in assessing the impact of DUT‐TAM on sexual function by linking numerical changes in MSHQ scores to spontaneously reported SexAEs for the first time. The threshold effect for incidence of SexAEs warrants further investigation to determine its clinical relevance.
format Online
Article
Text
id pubmed-7187250
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71872502020-04-28 Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study Roehrborn, Claus G. Rosen, Raymond C. Manyak, Michael J. Palacios‐Moreno, Juan Manuel Wilson, Timothy H. Lulic, Zrinka Giuliano, François Int J Clin Pract Original Papers ‐ Men's Health AIM: To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia. METHODS: This was a post hoc analysis of the Phase 4 FDC116115 study, in which patients aged ≥50 years were randomised 1:1 to receive a fixed‐dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (DUT‐TAM FDC), or placebo. End‐points included: change in MSHQ total scores by baseline characteristics and SexAEs; cumulative distribution function for change from baseline to month 12 in MSHQ total score and the ejaculation, erection, satisfaction and sexual desire (libido) domain scores; and relationship between changes in MSHQ scores and SexAEs. RESULTS: The intent‐to‐treat population comprised 489 patients (DUT‐TAM FDC, n = 243; placebo, n = 246). The mean reduction in total MSHQ score was greater in patients with SexAEs across both groups, compared with patients without SexAEs. Most patients reporting any SexAE (86% DUT‐TAM FDC, 67% placebo) had a worsening of the MSHQ total score at month 12 compared with baseline. Specifically, 90% (DUT‐TAM FDC) and 75% (placebo) of patients reporting an ejaculation SexAE and 73% (DUT‐TAM FDC) and 87% (placebo) of patients reporting an erection SexAE had a worsening of MSHQ ejaculation and erection domain scores, respectively, at month 12. A threshold effect for incident SexAE was observed; patients showing a decrease of approximately 6‐10 points in the total MSHQ score were more likely to report SexAEs. CONCLUSION: Findings support the clinical utility of the MSHQ tool in assessing the impact of DUT‐TAM on sexual function by linking numerical changes in MSHQ scores to spontaneously reported SexAEs for the first time. The threshold effect for incidence of SexAEs warrants further investigation to determine its clinical relevance. John Wiley and Sons Inc. 2020-02-11 2020-05 /pmc/articles/PMC7187250/ /pubmed/31927774 http://dx.doi.org/10.1111/ijcp.13480 Text en © 2020 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Papers ‐ Men's Health
Roehrborn, Claus G.
Rosen, Raymond C.
Manyak, Michael J.
Palacios‐Moreno, Juan Manuel
Wilson, Timothy H.
Lulic, Zrinka
Giuliano, François
Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
title Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
title_full Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
title_fullStr Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
title_full_unstemmed Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
title_short Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
title_sort men’s sexual health questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a post hoc analysis of a prospective, randomised, placebo‐controlled study
topic Original Papers ‐ Men's Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187250/
https://www.ncbi.nlm.nih.gov/pubmed/31927774
http://dx.doi.org/10.1111/ijcp.13480
work_keys_str_mv AT roehrbornclausg menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol
AT rosenraymondc menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol
AT manyakmichaelj menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol
AT palaciosmorenojuanmanuel menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol
AT wilsontimothyh menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol
AT luliczrinka menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol
AT giulianofrancois menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol